Sanwa BioTech Limited

Unit 2, 5/F, Wah Lei Industrial Centre, 10-14 Kwei Tei Street, Fo Tan, N.T
Hong Kong SAR,  000000

Hong Kong
https://www.sanwabiotech.com

• Booth: 4520

At Sanwa BioTech, we provide diagnostic solutions based on our microfluidic disposable Lab-On-Chip (LOC) platform, including an integrative point of care device, reagents, software analytics & data management service, which brings convenience and value in diseases monitoring and supports clinical decisions, improves patients health and contributes to innovative solutions that combat challenges on global health care.

 Press Releases

• ALiA BioTech’s one-stop diagnostic platform brings multiplex testing to the medical front line (May 03, 2023)

  Country Business Reports interviews and articles by Discovery Reports

  Discoveryreports.com

  Driven by the Covid-19 pandemic, the market for point-of-care testing (POCT) is seen to double in size compared to pre-pandemic levels. In this burgeoning field, multiplexing is the key technology differentiator. Increasing the number of simultaneous assays helps to identify the right biomarker, and thus reduces the cost and time it takes to quell any potential outbreak. ALiA BioTech Group took on this challenge 10 years ago, and is now ready to deploy a next-generation rapid diagnostic platform that can conduct multiplex testing in a single biochip within 15 minutes.

  “It becomes very personal now,” said Kelvin Chiu, CEO. “Next time we sneeze or cough, we could be catching Covid-19, influenza, respiratory syncytial virus or Streptococcus pneumoniae. A single test on our platform gives the fast track and accurate answer.”

  ALiA’s Lab-on-Chip platform is a patented POCT that delivers up to 30 results from a single drop of body fluid, whether that be blood, serum, swab or urine. Having completed research and development of its proprietary microfluidic and microarray technologies, ALiA is ready to scale up the manufacturing of multiplex products for different disease panels. The company’s pipeline will also direct POCT towards veterinary health and agri-food surveillance within the same platform.

  Click to Know More at: ALiA BioTech’s one-stop diagnostic platform brings multiplex testing to the medical front line | South China Morning Post (scmp.com)

• HK CE tours biotech company - Sanwa BioTech (May 03, 2023)

  Chief Executive Carrie Lam today visited a local biotech company in Fo Tan that has developed a portable rapid testing instrument.

  Mrs Lam learnt more about how the advanced manufacturing industry and re-industrialisation development have benefitted from the Government and the Hong Kong Science & Technology Parks Corporation's support in recent years.

  She toured the biotech company's research and development (R&D) facilities as well as the automated production line at its Fo Tan factory, where she received a briefing on its R&D projects and the progress of its product commercialisation.

  A partner company of the corporation, it has developed a portable testing instrument which can diagnose specific diseases with a single drop sample on a small chip in just 15 minutes, thus enabling healthcare personnel to conduct rapid testing and make clinical diagnoses early.

  The company has received more than $18 million in subsidies from the Innovation & Technology Fund, of which $12 million is from the Re-industrialisation Funding Scheme launched mid-2020 on a matching basis.

  It will move into the Advanced Manufacturing Centre being constructed by the corporation in Tseung Kwan O Industrial Estate to set up more production lines to transform research results into industrial products. The centre is expected to be completed next year.

  Mrs Lam noted that the corporation has developed the Precision Manufacturing Centre and three other centres, with a total investment of more than $9 billion, to help foster smart production.

  The Chief Executive said the current-term Government has been sparing no effort in promoting innovation and technology development in Hong Kong and that she believed re-industrialisation would provide new impetus for economic growth, create quality employment opportunities and enhance the city's competitiveness.

  This is supported by Hong Kong's strong R&D capability as well as the tremendous opportunities brought about by the National 14th Five-Year Plan and the Guangdong-Hong Kong-Macao Greater Bay Area development, Mrs Lam added.

  Click to Know More at: https://www.news.gov.hk/eng/2021/07/20210729/20210729_202729_212.html?type=ticker

• Start-Up Hong Kong: The Biotech Boom (May 03, 2023)

  Covid-19 has swept the world in the past year. Being able to make clinical diagnoses quickly and accurately is of crucial importance in combating the increasing threat of infectious diseases.

  Sanwa BioTech is a local biotech start‑up founded in 2012. Making use of disposable microfluidic “Lab‑on‑Chip” (LOC) technologies and portable and rapid testing instrument, it has developed a rapid virus testing device that helps shorten the waiting process and reduces the overwhelming workload of laboratory staff. Sanwa’s Chief Executive Officer Kelvin Chiu shared with us Hong Kong’s experience in developing biotech and his views on the local start‑up ecosystem. He is happy to see the policy support extended to biotech start‑ups at every stage of their development and hopes their successful experience can be replicated in other fields of innovation and technology to boost the growth of the local start‑up ecosystem.

  Click to Know More at: Start-Up Hong Kong: The Biotech Boom | HKTDC Research

 Additional Info